Fang et al. found that the activation of the EGFR/SRC/ERK pathway in GBM promotes the expression of YT521-B homology (YTH) domain-containing family protein 2 (YTHDF2), and YTHDF2 promotes tumor invasion by downregulating LXRα in an m6A-dependent mRNA decay manner, suggesting that YTHDF2 is a potential target for GBM therapy 40. Here, YTHDF2 is linked to neoplasm.